Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in Nonischemic Dilated Cardiomyopathy
NCT00574119Phase 4Completed
- Sponsor
- Vanderbilt University
- Start
- Dec 2007
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of spironolactone in non-ischemic dilated cardiomyopathy (NIDCM), sponsored by Vanderbilt University. Primary endpoints: Left Ventricular Work-metabolic Index at 6 months, Myocardial Perfusion Reserve Index at 6 months and 1 more. Started Dec 2007; status: completed.
02
Drugs
spironolactone
03
Conditions
non-ischemic dilated cardiomyopathy (NIDCM)
Beyond the preview
Go deeper on NCT00574119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574119.